Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female between, and including, 42 and 64 days of age at the time of the first vaccination~* Written informed consent obtained from parents/legal guardian of the subject~* Free of obvious health problems as established by medical history and/or clinical examination before entering the study~* Hepatitis B vaccination at birth (within 48 hours) Available for all scheduled study visits~Exclusion Criteria:~* Use of any investigational drug or any investigational vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up~* Planned administration of a vaccine not foreseen by the study protocol~* Known or suspected impairment of immune function, known Human immunodeficiency virus (HIV)-positivity, receiving immunosuppressive therapy, or having received systemic immunosuppressive therapy within 1 month prior to study entry (note: inhaled and topical steroids are allowed)~* Administration of parenteral immunoglobulin preparation and/or blood products since birth~* Previous vaccination against Haemophilus influenzae type b (Hib) and/or diphtheria, tetanus, pertussis (DTP)~* History of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component or to products containing mercury compounds, such as sodium ethylmercuro-thiosalicylate~* Significant acute infection~* Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives~* Participation in another clinical study

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 64 Days
- Healthy Volunteers: t

Study Arms:
- Quinvaxem (Type: EXPERIMENTAL): None
- Tritanrix Hib/HepB + Quinvaxem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).